BPC-157 10mg · Research brief

BPC 157 TB 500 Research Compound for Sale: Blend Formats

Real Peptides Research TeamEditorial

Updated September 28, 202610 min read

52 WORDS

Short answer

A vial stamped ' BPC-157 & TB-500 40mg' tells you almost nothing until you read the certificate that shipped with it. Forty milligrams could be a 20/20 split. It could be 10/30. Both go to market under the same product name, at similar prices, from suppliers who never publish the ratio anywhere.

Key takeaways

A BPC 157 TB 500 research compound is two synthetic peptides co-lyophilized in one vial, sold for in vitro and preclinical laboratory research only, and neither compound is an FDA-approved drug.
BPC-157 is a 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV), while TB-500 corresponds to the short active region of the 43-amino-acid protein thymosin beta-4.
The milligram figure on a blend label is the combined total, so a 40mg vial says nothing about whether the split is 20/20 or something else.
HPLC purity and component ratio are two different measurements, and most blend certificates report only the first.
Net peptide content is lower than gross vial weight because of residual TFA counterion and bound water, which only amino acid analysis or nitrogen determination resolves.
Both compounds are prohibited in competitive sport under World Anti-Doping Agency rules, and any supplier discussing human outcomes is outside its lane.

A vial stamped 'BPC-157 & TB-500 40mg' tells you almost nothing until you read the certificate that shipped with it. Forty milligrams could be a 20/20 split. It could be 10/30. Both go to market under the same product name, at similar prices, from suppliers who never publish the ratio anywhere.

Anyone comparing a BPC 157 TB 500 research compound for sale should read the paperwork before the price tag. We synthesize in small batches and test each one, so we see the distance between what blend labels claim and what analytical data confirms. It's wider than most buyers expect.

What is a BPC 157 TB 500 research compound for sale?

It is a single vial holding two synthetic peptides, BPC-157 and TB-500, co-lyophilized at a stated ratio and sold strictly for in vitro and preclinical laboratory research. Common formats run 5mg/5mg, 10mg/10mg and 40mg totals. Match the vial's lot number against its certificate of analysis before anything else.

The oversimplification worth killing early: a blend is not just two peptides sitting in one container, functionally identical to buying them separately. Co-lyophilization turns the ratio between the two actives into a manufacturing variable you cannot confirm by eye, and it makes purity reporting harder to interpret than a single-compound certificate. What follows covers what each peptide is, how ratios and milligram totals get labeled, why blend certificates mislead careless readers, and what to verify before you buy.

The two peptides in the vial, defined

BPC-157 is a pentadecapeptide: fifteen amino acids, sequence GEPPPGKPADDAGLV, representing a partial sequence of a protein isolated from human gastric juice. That's where the name Body Protection Compound comes from. The preclinical literature, almost entirely rodent and cell-culture work, examines its interaction with angiogenic signaling, including VEGFR2 and nitric oxide pathways. Research suggests effects on fibroblast migration in tendon and ligament models in vitro. None of this is established in controlled human trials, and BPC-157 is not an approved drug.

TB-500 is the synthetic counterpart to thymosin beta-4 (Tb4), a 43-amino-acid actin-sequestering protein found in most mammalian cells. Most material sold as TB-500 corresponds to the short active region around the LKKTETQ sequence rather than the full 43-residue protein. That distinction matters enormously, because the published work on Tb4 and the published work on the fragment are not interchangeable. The studied mechanism is actin binding: Tb4 holds G-actin monomers in reserve and influences polymerization, which shapes cell migration.

Pairing the two is a research convention, not a validated synergy. The rationale investigators give is pathway separation, angiogenic signaling on one side and cytoskeletal dynamics on the other. Whether the combination produces anything the compounds don't produce individually has not been settled in published work, and we won't pretend otherwise.

In our experience fielding questions from lab buyers, the most common misunderstanding is assuming TB-500 and thymosin beta-4 are the same molecule on a certificate. Mass spectrometry is what tells you which one you actually received.

Ratios, milligram totals and multi-peptide stacks

The number on a blend label is almost always combined mass, not the mass of either component. A 20mg blend is typically 10mg BPC-157 plus 10mg TB-500. A 40mg blend is usually 20/20. 'Usually' is doing real work in that sentence, because no labeling standard governs it. When a listing for a BPC 157 TB 500 research compound for sale states only a total, the split is an assumption until a certificate confirms it.

Three-component and five-component stacks stretch that ambiguity further. A GHK-Cu + BPC-157 + TB-500 research peptide blend adds glycyl-L-histidyl-L-lysine bound to copper(II), a tripeptide studied in collagen, skin and wound-model research. A BPC-157 + KPV research peptide pairs the pentadecapeptide with KPV, the lysine-proline-valine tripeptide that forms the C-terminal fragment of alpha-melanocyte-stimulating hormone and appears throughout anti-inflammatory signaling literature. Five-peptide stacks sold under the KLOW acronym are commonly listed as containing KPV, larazotide, GHK-Cu, BPC-157 and TB-500.

Every added component multiplies what a certificate has to demonstrate. Two peptides mean two identity confirmations and two content measurements. Five means five. A supplier publishing one purity percentage for a five-peptide vial is publishing a number that cannot mean what most buyers assume it means.

Copper complexes also behave differently on reverse-phase columns than uncomplexed peptides, which is one practical reason GHK-Cu is frequently supplied in its own vial rather than co-lyophilized with anything else.

Why a blend certificate is harder to read than a single-compound one

This is the part most sourcing guides skip entirely. On a single-compound vial, HPLC purity is intuitive: one main peak at 214nm, and purity is that peak's area as a percentage of total peak area. On a co-lyophilized blend, the chromatogram shows two main peaks, and purity becomes their combined area measured against everything else in the trace. A vial can legitimately report high purity and still be 15/5 instead of 10/10. Purity and ratio are two separate measurements, and only one of them typically appears on the summary sheet.

The second gap is net peptide content versus gross vial weight. Synthetic peptides purified by reverse-phase HPLC usually carry residual trifluoroacetic acid as a counterion, plus bound water. A vial filled to 10mg gross can hold meaningfully less actual peptide. Amino acid analysis or nitrogen determination resolves that; a purity figure never will.

The third is identity. HPLC tells you how many things are in the vial. Mass spectrometry tells you what they are. A blend certificate without MS confirmation for each component has quantified something without identifying it.

Practically, that means asking for the chromatogram and the mass spec trace, not the one-page summary. Our team reviews batch documentation against exactly these three gaps before release. Everything here is educational information about laboratory materials, and compliance, handling and safety decisions belong with your institution's oversight process.

What separates a real research supplier from a repackager

Regulatory status is the fastest filter available. Neither BPC-157 nor TB-500 is an FDA-approved drug, and the FDA has flagged BPC-157 among bulk substances it declined to permit in compounded preparations on safety grounds. Both are prohibited in competitive sport: thymosin beta-4 sits in the World Anti-Doping Agency's growth factor category, and BPC-157 is handled as a non-approved substance under WADA rules. Any listing for a BPC 157 TB 500 research compound for sale that talks about healing, recovery or human protocols is describing something it has no license to describe.

What a legitimate supplier does: small-batch synthesis with verified amino-acid sequencing, lot-specific certificates whose numbers match the vial, HPLC alongside mass spectrometry, and research-use-only labeling that never drifts into consumption language. What it doesn't do is pair vials with injection supplies, publish preparation charts, or answer questions about quantities for a person or an animal.

That last one comes up constantly. People ask about pets. That question belongs with a licensed veterinarian who can actually examine the animal, so talk to your veterinarian rather than a peptide supplier.

Storage is the quiet variable nobody markets. Lyophilized peptides are generally held at -20C, protected from light and moisture, because dry powder is substantially more stable than anything in solution. Temperature excursions in transit don't announce themselves. The powder looks identical either way, which is why cold-chain handling and a recent synthesis date matter more than a discount code.

Blend formats side by side

Not every BPC 157 TB 500 research compound for sale is built the same way, and the format changes which documentation a lab should demand. This compares the configurations most commonly listed by suppliers.

Format	How it is usually labeled	What the certificate must show	Professional assessment
Two single vials purchased together	BPC-157 10mg and TB-500 10mg, priced and shipped as separate items	One chromatogram, one MS trace and one content figure per vial	Cleanest option analytically, because each compound is verified independently and ratio error is impossible
Co-lyophilized 10mg/10mg blend	Often written as 20mg blend or 10/10	Combined purity plus a stated ratio confirmed by content analysis, not just purity	Acceptable when the ratio is documented; a purity-only certificate leaves the split unverified
40mg blend	Marketed as bpc-157 and tb-500 40mg research, ratio frequently omitted	Component masses stated individually, since 40mg alone could describe several splits	Treat an unstated ratio as missing data rather than a 20/20 assumption
GHK-Cu + BPC-157 + TB-500	Three-peptide blend, sometimes with copper content listed separately	Three identity confirmations plus copper coordination detail for the GHK-Cu fraction	Copper chemistry complicates analysis; separate vials are usually the more defensible sourcing choice
BPC-157 + KPV	Two-peptide gut and inflammation research pairing	Distinct MS confirmation for a 15-residue peptide and a 3-residue tripeptide	Easy to verify when documented, since the two masses are far apart on an MS trace

What If: sourcing and handling scenarios

What if the vial arrives labeled 40mg with no ratio stated?

Request the batch certificate showing individual component masses before the material enters any study record. Forty milligrams is a total, and without a documented split the experimental variable is undefined from the first day. If the supplier can only produce a purity percentage, the ratio has not been measured, it has been assumed. Undocumented material is unusable for anything you intend to publish or repeat.

What if the lyophilized powder looks like a thin film rather than a solid cake?

Photograph it, record the lot number, and contact the supplier before doing anything else. Cake appearance depends on fill volume, freeze-drying cycle and the mass in the vial, so a low-fill 5mg vial legitimately looks like film while a 20mg vial looks like a plug. Appearance alone is not evidence of degradation, but it is worth documenting alongside shipping temperature records. The literature does not define a standard visual specification for co-lyophilized multi-peptide vials.

What if the lot number on the vial doesn't match the certificate?

Treat the mismatch as a failed chain of custody and quarantine the vial. A certificate that doesn't correspond to the specific batch in front of you is a generic marketing document, not analytical data, and it tells you nothing about the material you hold. Reputable suppliers issue certificates per production batch and can reissue the correct one within a day. A supplier who cannot is repackaging someone else's synthesis.

What if a five-peptide stack costs less than two single vials?

Check the per-component masses before assuming it's a bargain. Five-peptide stacks often carry small quantities of each constituent, so the headline total can exceed what two single-compound vials contain while delivering less of the two compounds a study actually needs. Price per milligram of the specific peptide you're investigating is the only comparison that means anything. Cheap stacks are frequently light on the expensive components.

The honest truth about blended research peptides

Here's the honest answer: the blend format exists for convenience and margin, not because the science requires it. There is no published evidence establishing that co-lyophilizing BPC-157 with TB-500 produces an effect the separate compounds don't, and combining them in one vial costs a laboratory the ability to vary either independently. For any study where the ratio is a variable rather than a fixed assumption, separate vials are the better instrument. Blends make sense for cost per milligram and for simplified inventory. They do not make sense for analytical precision, and any supplier telling you otherwise is selling packaging as pharmacology.

If you're building a research inventory, single-compound vials remain the cleanest starting point: BPC-157 10mg and TB-500 10mg can be documented independently, while KPV and GHK-Cu cover the stack components most often requested alongside them. Batch documentation for the catalog sits on our certificates of analysis page, with multi-compound research bundles listed separately from oral research compounds.

Every BPC 157 TB 500 research compound for sale is, underneath the marketing, a document problem wearing a chemistry costume. The molecules themselves are well characterized and research-grade synthesis is a solved problem. Verification is not, because the moment two peptides share a vial, a buyer loses the ability to confirm anything by inspection and becomes entirely dependent on paperwork produced by the seller. Suppliers understand this perfectly. The ones who publish full chromatograms and mass spec traces without being asked are telling you something about themselves that no product description ever could.

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

It contains two synthetic peptides in one vial: BPC-157, a 15-amino-acid pentadecapeptide, and TB-500, which corresponds to the active region of the 43-amino-acid protein thymosin beta-4. They are co-lyophilized as a dry powder at a stated ratio, most commonly 5mg/5mg or 10mg/10mg. The material is supplied for in vitro and preclinical laboratory research only and is not an approved drug.

Match the lot number on the vial to the lot number on the certificate of analysis, then look for two things the summary sheet often omits: the HPLC chromatogram and mass spectrometry confirmation for each component. Purity tells you how much non-target material is present; it does not tell you the ratio between the two actives. Ask for component masses stated individually rather than as a combined total.

It almost always refers to the combined mass of both peptides, not the mass of either one. A 40mg blend is commonly 20mg BPC-157 plus 20mg TB-500, but no labeling standard enforces that, so a 10/30 split can carry the identical label. Until the certificate lists each component separately, the split should be treated as unverified.

Separate vials are analytically cleaner because each compound is independently verified and the ratio can be varied by the researcher rather than fixed by the manufacturer. Blends are simpler for inventory and often cheaper per milligram. For any study where the ratio is itself a variable, single-compound vials are the appropriate choice.

Pricing varies widely depending on total milligrams, whether the material is third-party tested, and how much analytical documentation is published. The more useful comparison is price per milligram of the specific compound being studied rather than price per vial, since blend totals can disguise small quantities of the more expensive component. Unusually low pricing on multi-peptide stacks often reflects light loading of one constituent.

They are sold in many jurisdictions as research-use-only chemicals, not as drugs, and neither is FDA-approved. The FDA has flagged BPC-157 among bulk substances it declined to permit in compounded preparations on safety grounds, and both compounds are prohibited in competitive sport under World Anti-Doping Agency rules. Buyers are responsible for confirming the rules that apply to their own institution and location.

It is a three-component blend adding GHK-Cu, the tripeptide glycyl-L-histidyl-L-lysine bound to copper(II), to the standard two-peptide combination. GHK-Cu appears widely in collagen, skin and wound-model research literature. Because copper complexes behave differently on reverse-phase chromatography than uncomplexed peptides, separate vials are often the more defensible sourcing option for analytical clarity.

KPV is a tripeptide of lysine, proline and valine that forms the C-terminal fragment of alpha-melanocyte-stimulating hormone, and it appears throughout anti-inflammatory signaling research. A BPC-157 + KPV research peptide pairs it with the pentadecapeptide in gut and inflammation model work. The two molecules differ substantially in mass, which makes identity confirmation by mass spectrometry straightforward on a shared certificate.

Lyophilized peptide powder is generally held at -20C, protected from light and moisture, because dry material is considerably more stable than anything in solution. Temperature excursions during shipping are not visible in the appearance of the powder, which is why cold-chain handling records and a recent synthesis date carry more weight than visual inspection. Specific handling decisions should follow your institution's safety and compliance procedures.

No. Thymosin beta-4 is a 43-amino-acid actin-sequestering protein found in most mammalian cells, while most material sold as TB-500 corresponds to a much shorter fragment around the LKKTETQ sequence. This matters because published research on the full protein and research on the fragment are not interchangeable. Mass spectrometry on the certificate is what confirms which molecule is in the vial.

Yes. Every catalog compound is synthesized in small batches with verified amino-acid sequencing, and batch documentation is published rather than furnished only on request. Certificates are lot-specific, so the number on the vial should match the number on the document exactly. A certificate that does not correspond to your specific batch is a marketing sheet, not analytical data.

No. Every peptide discussed here is supplied strictly for laboratory research and is not intended for human or veterinary consumption, and no preparation or administration information is provided with them. Anyone with a health question about an animal should talk to their veterinarian, and anyone with a personal health question should speak with a licensed physician.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA